Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib with or without methotrexate versus adalimumab with methotrexate in moderately to severely active rheumatoid arthritis
2014-000358-13Phase 3Completed
- Sponsor
- Pfizer
- Start
- Aug 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Tofacitinib monotherapy, Tofacitinib plus methotrexate and Adalimumab plus methotrexate (3 arms). Primary endpoint: ACR50 response rate at Month 6. Started Aug 2014; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2014-000358-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000358-13.